Roche Holding AG ROG.S said on Friday it was withdrawing its immunotherapy, Tecentriq, for the treatment of a type of breast cancer in the United States following a consultation with the Food and Drug Administration.
The decision does not affect other approved indications for Tecentriq in the United States, the company said.
The move was not related to any changes in either the efficacy or safety associated with Tecentriq, it said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.